Hot Features
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company’s pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an inv... Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company’s pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.607 | -7.16646989374 | 8.47 | 8.53 | 7.7 | 18595 | 8.29114476 | CS |
| 4 | 0.083 | 1.06683804627 | 7.78 | 8.9999 | 7.6 | 62944 | 8.56946159 | CS |
| 12 | 7.3517 | 1437.84470956 | 0.5113 | 9.2499 | 0.5 | 54654 | 7.27318686 | CS |
| 26 | 7.1337 | 978.157136981 | 0.7293 | 9.2499 | 0.4618 | 282726 | 1.21705231 | CS |
| 52 | 7.1963 | 1079.39103045 | 0.6667 | 9.2499 | 0.4618 | 436277 | 0.89679585 | CS |
| 156 | 4.883 | 163.859060403 | 2.98 | 9.2499 | 0.4618 | 730749 | 1.1613657 | CS |
| 260 | -7.137 | -47.58 | 15 | 27.95 | 0.4618 | 501258 | 1.47950526 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.